KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Research & Development: 2009-2025

Historic Research & Development for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to $217.8 million.

  • Ionis Pharmaceuticals' Research & Development fell 0.91% to $217.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $881.5 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $901.5 million for FY2024, which is 0.21% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Research & Development is $217.8 million, which was up 0.14% from $217.5 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Research & Development peaked at $308.3 million during Q4 2022, and registered a low of $139.3 million during Q2 2021.
  • Over the past 3 years, Ionis Pharmaceuticals' median Research & Development value was $217.8 million (recorded in 2025), while the average stood at $221.6 million.
  • In the last 5 years, Ionis Pharmaceuticals' Research & Development surged by 71.67% in 2022 and then fell by 16.78% in 2023.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Research & Development stood at $179.6 million in 2021, then surged by 71.67% to $308.3 million in 2022, then declined by 16.78% to $256.6 million in 2023, then fell by 4.31% to $245.5 million in 2024, then fell by 0.91% to $217.8 million in 2025.
  • Its Research & Development stands at $217.8 million for Q3 2025, versus $217.5 million for Q2 2025 and $200.8 million for Q1 2025.